| Item 7.01 | Regulation FD Disclosure. |
On March 25, 2019, Aimmune Therapeutics, Inc. (“Aimmune” or the “Company”) issued a press release announcing the topline results of its Phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (AR101Trial inEuropeMeasuring oralImmunotherapySuccess) (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
The Company is also hosting an investor conference call at 8:30 AM PT (8:00 AM ET) on Monday, March 25, 2019 to discuss the topline results from the Company’s ARTEMIS study of AR101. Conference call information is as follows:
Conference Call Numbers –1-877-497-1438 (domestic) or1-262-558-6296 (international); Conference ID# 5157603
The information in this Item 7.01 of this Current Report on Form8-K, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
On March 25, 2019, Aimmune announced that its Phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS, met its primary efficacy endpoint. Topline data show that the proportion of AR101-treated patients who tolerated a1,000-mg dose of peanut protein (2,043 mg cumulative) in a blinded exit challenge after approximately nine months of AR101 treatment was significantly higher (p<0.00001) than in the placebo group. Specifically, the median tolerated dose of peanut protein for AR101-treated patients improved100-fold, from 10 mg at baseline to 1,000 mg at exit. The trial also greatly exceeded a 15% lower-bound of the 95% confidence interval (CI) of the difference between treatment arms for all endpoints.
In addition, the safety profile and completion rate observed in ARTEMIS are consistent with the results seen in previous AR101 clinical trials. Notably, no cases of anaphylaxis or of eosinophilic esophagitis (EoE) were observed. Aimmune plans to present full results in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in early June.
The randomized, double-blind, placebo-controlled Phase 3 ARTEMIS clinical trial enrolled 175 children and adolescents ages 4 to 17 from 18 sites in France, Germany, Ireland, Italy, Spain, Sweden and the United Kingdom. Patients underwent approximately six months of dose escalation and then three months at a daily therapeutic dose of AR101 at 300 mg or placebo, followed by an exit double-blind, placebo-controlled food challenge. The primary efficacy endpoint was patients’ ability to tolerate a1,000-mg single dose of peanut protein, the equivalent of approximately three to four peanut kernels (2,043 mg cumulative, equivalent to seven or eight peanut kernels).
Based on the results from ARTEMIS, Aimmune intends to submit a marketing authorization application (MAA) for AR101 to the European Medicines Agency (EMA) inmid-2019.
| Item 9.01 | Financial Statements and Exhibits. |
